Author: admin

The Myasthenia Gravis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Myasthenia Gravis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myasthenia Gravis Market.

Some of the key takeaways from the Myasthenia Gravis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Myasthenia Gravis treatment therapies with a considerable amount of success over the years.

• Myasthenia Gravis companies working in the treatment market are Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio, Alexion Pharmaceuticals, Takeda, Cartesian Therapeutics, RemeGen, Horizon Therapeutics, and others, are developing therapies for the Myasthenia Gravis treatment

• Emerging Myasthenia Gravis therapies in the different phases of clinical trials are- Povetacicept, TOL 2, MuSK-CAART, RLYB116, ALXN2050, TAK-079, Descartes-08, Telitacicept, Inebilizumab, and others are expected to have a significant impact on the Myasthenia Gravis market in the coming years.

• In December 2024, Cartesian Therapeutics has released updated efficacy and safety findings from its Phase IIb trial evaluating Descartes-08, an mRNA cell therapy candidate for generalized myasthenia gravis (MG). The results showed sustained responses at the 12-month mark. The trial (NCT06038474) was a double-blind, placebo-controlled, crossover study conducted in an open-label format, involving 36 severely symptomatic, heavily pre-treated patients. Half of the participants received a placebo, while the other half were treated with Descartes-08. Both groups underwent six weekly outpatient infusions without the need for preconditioning chemotherapy.

• In December 2024, Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company specializing in engineered natural killer (NK) cell therapies, has announced the initiation of enrollment for the Ntrust-2 trial and the IND clearance for an investigator-sponsored trial (IST) of NKX019. NKX019 is Nkarta’s allogeneic, CD19-directed CAR NK-cell therapy, which will be evaluated in patients with myasthenia gravis (MG). The multi-center Ntrust-2 trial will assess NKX019 across three cohorts, including systemic sclerosis (SSc/scleroderma), idiopathic inflammatory myopathy (IIM/myositis), and ANCA-associated vasculitis (AAV). The IST will be conducted by researchers at the University of California, Irvine, and the University of Kansas Medical Center.

• In August 2024, Merck KGaA (Merck) administered the first dose in a Phase III clinical trial evaluating oral Cladribine for the treatment of generalized myasthenia gravis (gMG), a rare neuromuscular condition. Named MyClad, this global, randomized, double-blind, placebo-controlled study is designed to assess the efficacy and safety of Cladribine capsules in comparison to a placebo.

• In June 2024, Johnson & Johnson (NYSE: JNJ) announced positive results from the Phase 3 Vivacity-MG3 study of nipocalimab in patients with generalized myasthenia gravis (gMG). Patients receiving nipocalimab alongside standard care (SOC) showed superior improvement over those receiving placebo plus SOC, as measured by the primary endpoint of the MG-ADL score improvement from baseline over 24 weeks. These findings are part of a presentation and one of eight abstracts Johnson & Johnson will present at the European Academy of Neurology (EAN) 2024 Congress and will be included in regulatory submissions later this year.

• In January 2024, Cartesian Therapeutics’ Descartes-08, an investigational autologous mRNA-engineered chimeric antigen receptor T-cell (CAR-T) therapy for autoimmune diseases like myasthenia gravis (MG), has shown clinically significant improvements in the phase 2a part of a clinical trial (NCT04146051) for MG. All 7 patients in the phase 2a portion, treated with a single infusion of Descartes-08 weekly for 6 weeks, demonstrated substantial and lasting clinical improvements in MG Composite, MG Activities of Daily Living, Quantitative MG scores, and Quality of Life 15-revised assessments at 9 months post-treatment.

• In January 2024, RYSTIGGO® (rozanolixizumab-noli) is a specialized treatment for adults with generalized myasthenia gravis (gMG) who test positive for anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibodies. Created by the Belgian biopharmaceutical company UCB, RYSTIGGO is provided in a single-dose vial containing 280mg/2ml (140mg/ml) of a colorless to light brownish-yellow solution, intended for subcutaneous injection.

Myasthenia Gravis Overview

Myasthenia Gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by weakness and rapid fatigue of voluntary muscles. The name, which translates to “grave muscle weakness,” reflects the primary symptom of the condition. MG occurs when the immune system produces antibodies that interfere with the communication between nerves and muscles.

Get a Free Sample PDF Report to know more about Myasthenia Gravis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/myasthenia-gravis-pipeline-insight

Emerging Myasthenia Gravis Drugs Under Different Phases of Clinical Development Include:

• Povetacicept: Alpine Immune Science

• TOL 2: Toleranzia

• MuSK-CAART: Cabaletta Bio

• RLYB116: Rallybio

• ALXN2050: Alexion Pharmaceuticals

• TAK-079: Takeda

• Descartes-08: Cartesian Therapeutics

• Telitacicept: RemeGen

• Inebilizumab: Horizon Therapeutics

Myasthenia Gravis Route of Administration

Myasthenia Gravis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Infusion

• Intradermal

• Intramuscular

• Intranasal

• Intravaginal

• Oral

• Parenteral

• Subcutaneous

• Topical

• Molecule Type

Myasthenia Gravis Molecule Type

Myasthenia Gravis Products have been categorized under various Molecule types, such as

• Vaccines

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Product Type

Myasthenia Gravis Pipeline Therapeutics Assessment

• Myasthenia Gravis Assessment by Product Type

• Myasthenia Gravis By Stage and Product Type

• Myasthenia Gravis Assessment by Route of Administration

• Myasthenia Gravis By Stage and Route of Administration

• Myasthenia Gravis Assessment by Molecule Type

• Myasthenia Gravis by Stage and Molecule Type

DelveInsight’s Myasthenia Gravis Report covers around 22+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Myasthenia Gravis product details are provided in the report. Download the Myasthenia Gravis pipeline report to learn more about the emerging Myasthenia Gravis therapies

Some of the key companies in the Myasthenia Gravis Therapeutics Market include:

Key companies developing therapies for Myasthenia Gravis are – CuraVac, Grifols SA, Immunovant, Mitsubishi Tanabe Pharma, Novartis, Alexion Pharmaceutical, Argenx, Astellas Pharma, UCB Pharma, Bausch Health, and others.

Myasthenia Gravis Pipeline Analysis:

The Myasthenia Gravis pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Myasthenia Gravis with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myasthenia Gravis Treatment.

• Myasthenia Gravis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Myasthenia Gravis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myasthenia Gravis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Myasthenia Gravis drugs and therapies

Myasthenia Gravis Pipeline Market Drivers

• Increasing prevalence of Myasthenis gravis, growing awareness regarding the myasthenia gravis diagnosis options, surge in geriatric population with autoimmune disease are some of the important factors that are fueling the Myasthenia Gravis Market.

Myasthenia Gravis Pipeline Market Barriers

• However, limited reimbursement policies, high cost associated with the treatment and other factors are creating obstacles in the Myasthenia Gravis Market growth.

Scope of Myasthenia Gravis Pipeline Drug Insight

• Coverage: Global

• Key Myasthenia Gravis Companies: Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio, Alexion Pharmaceuticals, Takeda, Cartesian Therapeutics, RemeGen, Horizon Therapeutics, and others

• Key Myasthenia Gravis Therapies: Povetacicept, TOL 2, MuSK-CAART, RLYB116, ALXN2050, TAK-079, Descartes-08, Telitacicept, Inebilizumab, and others

• Myasthenia Gravis Therapeutic Assessment: Myasthenia Gravis current marketed and Myasthenia Gravis emerging therapies

• Myasthenia Gravis Market Dynamics: Myasthenia Gravis market drivers and Myasthenia Gravis market barriers

Request for Sample PDF Report for Myasthenia Gravis Pipeline Assessment and clinical trials

Table of Contents

1. Myasthenia Gravis Report Introduction

2. Myasthenia Gravis Executive Summary

3. Myasthenia Gravis Overview

4. Myasthenia Gravis- Analytical Perspective In-depth Commercial Assessment

5. Myasthenia Gravis Pipeline Therapeutics

6. Myasthenia Gravis Late Stage Products (Phase II/III)

7. Myasthenia Gravis Mid Stage Products (Phase II)

8. Myasthenia Gravis Early Stage Products (Phase I)

9. Myasthenia Gravis Preclinical Stage Products

10. Myasthenia Gravis Therapeutics Assessment

11. Myasthenia Gravis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Myasthenia Gravis Key Companies

14. Myasthenia Gravis Key Products

15. Myasthenia Gravis Unmet Needs

16 . Myasthenia Gravis Market Drivers and Barriers

17. Myasthenia Gravis Future Perspectives and Conclusion

18. Myasthenia Gravis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Myasthenia Gravis Pipeline 2024: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights By DelveInsights | Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio

“Metastatic Prostate Cancer Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Prostate Cancer Market.

The Metastatic Prostate Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Metastatic Prostate Cancer Pipeline Report:

• Companies across the globe are diligently working toward developing novel Metastatic Prostate Cancer treatment therapies with a considerable amount of success over the years.

• Metastatic Prostate Cancer companies working in the treatment market are Curium, Merck/ Orion, Pfizer, AstraZeneca, Telix Pharmaceuticals, Tavanta Therapeutics, Candel Therapeutics, Jiangsu Hengrui Pharmaceuticals, and others, are developing therapies for the Metastatic Prostate Cancer treatment

• Emerging Metastatic Prostate Cancer therapies in the different phases of clinical trials are- 177Lu-PSMA-I&T, Opevesostat (MK-5684), 177Lu-DOTA-rosopatamab, Cabozantinib, Capivasertib, Masitinib, FPI-2265, 177Lu-PNT2002, Mevrometostat (PF-06821497), Fuzuloparib, ModraDoc006, BMS-986218, Lorigerlimab, SX-682, ZEN-3694, Vudalimab, OPDIVO (nivolumab), Zenocutuzumab, Vobramitamab Duocarmazine, PT-112, LAE201, TAVT-45, pTVG-HP (MVI-816), TAS-115, KPG-121, ARV-766, CAN-2409, Saruparib (AZD5305), 177Lu-rhPSMA-10.1, Tazemetostat (Tazverik), KEYTRUDA, LAVA-1207, Masofaniten (EPI-7386), P PSMA 101, JANX 007, AUR107, MSP008-22, 225Ac-FL-020, NPX267, ABBV-969, SL-T10, Abivertinib, ETX-19477, AVA 6000, QXL138AM, BG-68501, DB-1311, and others are expected to have a significant impact on the Metastatic Prostate Cancer market in the coming years.

• In December 2024, Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical-stage biopharmaceutical company specializing in multimodal biological immunotherapies for cancer treatment, has announced results from a multicenter Phase 3 clinical trial assessing CAN-2409 viral immunotherapy in patients with localized prostate cancer.

• In November 2024, The US Food and Drug Administration (FDA) has accepted Bayer’s supplemental new drug application (sNDA) for its oral androgen receptor inhibitor (ARi), Nubeqa (darolutamide), for treating metastatic hormone-sensitive prostate cancer (mHSPC). The therapy is used in combination with androgen deprivation therapy (ADT). The sNDA submission is supported by positive findings from the Phase III ARANOTE trial, where the combination treatment achieved its primary endpoint by significantly improving radiological progression-free survival (rPFS).

• In September 2024, Ipsen announced that the Phase III CONTACT-02 trial for Cabometyx and atezolizumab in mCRPC showed a non-significant improvement in overall survival but met the progression-free survival (PFS) endpoint.

• In August 2024, Nuvation Bio announced that the US Food and Drug Administration has approved its investigational new drug application to assess NUV-1511, the first clinical candidate developed from the company’s innovative drug-drug conjugate (DDC) platform.

• In July 2024, The FDA has awarded fast-track designation to SYNC-T SV-102 for the treatment of metastatic castrate-resistant prostate cancer (mCRPC).

• In June 2024, Kangpu Biopharmaceuticals obtained FDA approval to conduct a Phase II/III trial of KPG-121 in combination with Abiraterone for metastatic castrate-resistant prostate cancer (mCRPC).

• In June 2024, BioNTech SE and Duality Biologics announced that the US Food and Drug Administration has granted Fast Track designation to BNT324/DB-1311 for treating patients with advanced, unresectable, or metastatic castration-resistant prostate cancer (CRPC) who have experienced progression following standard systemic treatments.

• In May 2024, Fusion Pharmaceuticals has launched the Phase II AlphaBreak trial to evaluate FPI-2265 in patients with metastatic castrate-resistant prostate cancer (mCRPC).

• In February 2024, Fusion Pharmaceuticals Inc. announced that it has entered into an exclusive worldwide licensing agreement with Heidelberg University and Euratom, represented by the European Commission, Joint Research Centre. This agreement grants Fusion exclusive global rights to use, develop, manufacture, and commercialize compounds covered by the patent, including 225Ac-PSMA I&T for treating prostate-specific membrane antigen (PSMA)-expressing cancers. Additionally, Fusion and the Licensors have reached an agreement to resolve a dispute regarding an inter partes review of a U.S. patent owned by the Licensors, initiated in August 2023 by the United States Patent and Trademark Office.

• In February 2024, BioXcel Therapeutics, Inc. announced that the FDA has granted Fast Track designation to BXCL701 in combination with a CPI for the treatment of metastatic small cell neuroendocrine prostate cancer (SCNC) in patients who are progressing on chemotherapy. This designation facilitates faster development and review by the FDA.

Metastatic Prostate Cancer Overview

Metastatic prostate cancer is an advanced stage of prostate cancer in which cancer cells spread from the prostate gland to other parts of the body, such as the bones, lymph nodes, liver, or lungs. This occurs when cancer cells break away from the primary tumor and travel through the bloodstream or lymphatic system to form secondary tumors. Symptoms may include bone pain, difficulty urinating, fatigue, and weight loss. Treatment for metastatic prostate cancer focuses on slowing the cancer’s progression, managing symptoms, and improving quality of life, using options like hormone therapy, chemotherapy, immunotherapy, and targeted therapies.

Get a Free Sample PDF Report to know more about Metastatic Prostate Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/metastatic-prostate-cancer-pipeline-insight

Emerging Metastatic Prostate Cancer Drugs Under Different Phases of Clinical Development Include:

• 177Lu-PSMA-I&T: Curium

• Opevesostat (MK-5684; ODM-208): Merck/ Orion

• Mevrometostat (PF-06821497): Pfizer

• TRUQAP (capivasertib, AZD5363): AstraZeneca

• 177Lu-DOTA-rosopatamab (TLX591): Telix Pharmaceuticals

• TAVT-45 (abiraterone acetate): Tavanta Therapeutics

• Saruparib (AZD5305): AstraZeneca

• CAN-2409 (aglatimagene besadenovec): Candel Therapeutics

• Fuzuloparib: Jiangsu Hengrui Pharmaceuticals

Metastatic Prostate Cancer Route of Administration

Metastatic Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Metastatic Prostate Cancer Molecule Type

Metastatic Prostate Cancer Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Metastatic Prostate Cancer Pipeline Therapeutics Assessment

• Metastatic Prostate Cancer Assessment by Product Type

• Metastatic Prostate Cancer By Stage and Product Type

• Metastatic Prostate Cancer Assessment by Route of Administration

• Metastatic Prostate Cancer By Stage and Route of Administration

• Metastatic Prostate Cancer Assessment by Molecule Type

• Metastatic Prostate Cancer by Stage and Molecule Type

DelveInsight’s Metastatic Prostate Cancer Report covers around 85+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Metastatic Prostate Cancer product details are provided in the report. Download the Metastatic Prostate Cancer pipeline report to learn more about the emerging Metastatic Prostate Cancer therapies

Some of the key companies in the Metastatic Prostate Cancer Therapeutics Market include:

Key companies developing therapies for Metastatic Prostate Cancer are – MacroGenics, Syntrix Pharmaceuticals, Zenith Epigenetics, Xencor, Bristol Myers Squibb, Merus, Phosplatin Therapeutics, Laekna Therapeutics, Tavanta Therapeutics, Madison Vaccines, Taiho Pharmaceutical, Kangpu Biopharmaceuticals, Arvinas, Candel Therapeutics, Blue Earth Therapeutics, Ipsen Biopharmaceuticals, LAVA Therapeutics, Curium, Merck, Telix Pharmaceuticals, Exelixis, AstraZeneca, AB Science, Lantheus, Pfizer, Jiangsu Hengrui Pharmaceuticals, Modra Pharmaceuticals, Bristol-Myers Squibb, Essa Pharma, Poseida Therapeutics, Janux Therapeutics, Aurigene Oncology, Sathgen Therapeutics, Full-Life Technologies, NextPoint Therapeutics, AbbVie, SL VAXiGEN, Sorrento Therapeutics, Inc., 858 Therapeutics, Avacta Life Sciences Ltd, Nammi Therapeutics, BeiGene, DualityBio, and others.

Metastatic Prostate Cancer Pipeline Analysis:

The Metastatic Prostate Cancer pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Prostate Cancer with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Prostate Cancer Treatment.

• Metastatic Prostate Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Metastatic Prostate Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Prostate Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Metastatic Prostate Cancer drugs and therapies

Metastatic Prostate Cancer Pipeline Market Drivers

• Growing Incidence of Prostate Cancer, Innovative Therapeutic Developments, Government and Non-Profit Funding Support, Aging Population, are some of the important factors that are fueling the Metastatic Prostate Cancer Market.

Metastatic Prostate Cancer Pipeline Market Barriers

• However, High Cost of Drug Development, Complex Disease Mechanism, Regulatory Hurdles, Adverse Side Effects of Treatments, and other factors are creating obstacles in the Metastatic Prostate Cancer Market growth.

Scope of Metastatic Prostate Cancer Pipeline Drug Insight

• Coverage: Global

• Key Metastatic Prostate Cancer Companies: Curium, Merck/ Orion, Pfizer, AstraZeneca, Telix Pharmaceuticals, Tavanta Therapeutics, Candel Therapeutics, Jiangsu Hengrui Pharmaceuticals, and others

• Key Metastatic Prostate Cancer Therapies: 177Lu-PSMA-I&T, Opevesostat (MK-5684), 177Lu-DOTA-rosopatamab, Cabozantinib, Capivasertib, Masitinib, FPI-2265, 177Lu-PNT2002, Mevrometostat (PF-06821497), Fuzuloparib, ModraDoc006, BMS-986218, Lorigerlimab, SX-682, ZEN-3694, Vudalimab, OPDIVO (nivolumab), Zenocutuzumab, Vobramitamab Duocarmazine, PT-112, LAE201, TAVT-45, pTVG-HP (MVI-816), TAS-115, KPG-121, ARV-766, CAN-2409, Saruparib (AZD5305), 177Lu-rhPSMA-10.1, Tazemetostat (Tazverik), KEYTRUDA, LAVA-1207, Masofaniten (EPI-7386), P PSMA 101, JANX 007, AUR107, MSP008-22, 225Ac-FL-020, NPX267, ABBV-969, SL-T10, Abivertinib, ETX-19477, AVA 6000, QXL138AM, BG-68501, DB-1311, and others

• Metastatic Prostate Cancer Therapeutic Assessment: Metastatic Prostate Cancer current marketed and Metastatic Prostate Cancer emerging therapies

• Metastatic Prostate Cancer Market Dynamics: Metastatic Prostate Cancer market drivers and Metastatic Prostate Cancer market barriers

Request for Sample PDF Report for Metastatic Prostate Cancer Pipeline Assessment and clinical trials

Table of Contents

1. Metastatic Prostate Cancer Report Introduction

2. Metastatic Prostate Cancer Executive Summary

3. Metastatic Prostate Cancer Overview

4. Metastatic Prostate Cancer- Analytical Perspective In-depth Commercial Assessment

5. Metastatic Prostate Cancer Pipeline Therapeutics

6. Metastatic Prostate Cancer Late Stage Products (Phase II/III)

7. Metastatic Prostate Cancer Mid Stage Products (Phase II)

8. Metastatic Prostate Cancer Early Stage Products (Phase I)

9. Metastatic Prostate Cancer Preclinical Stage Products

10. Metastatic Prostate Cancer Therapeutics Assessment

11. Metastatic Prostate Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Metastatic Prostate Cancer Key Companies

14. Metastatic Prostate Cancer Key Products

15. Metastatic Prostate Cancer Unmet Needs

16 . Metastatic Prostate Cancer Market Drivers and Barriers

17. Metastatic Prostate Cancer Future Perspectives and Conclusion

18. Metastatic Prostate Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Prostate Cancer Pipeline 2024: FDA Approvals, Therapies, Clinical Trials, and Latest Developments Unveiled by DelveInsight | Curium, Merck/ Orion, Pfizer, AstraZeneca, Telix Pharma, Tavanta

“Allergic Rhinitis Treatment Market”

(Albany, USA) DelveInsight’s “Allergic Rhinitis Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Allergic Rhinitis, historical and forecasted epidemiology as well as the Allergic Rhinitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Allergic Rhinitis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Allergic Rhinitis market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Allergic Rhinitis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Allergic Rhinitis market.

Request for a Free Sample Report @ Allergic Rhinitis Market Forecast

Some facts of the Allergic Rhinitis Market Report are:

• In 2023, the Allergic Rhinitis market size was highest in the US among the 7MM, accounting for approximately USD 3,496 million which is further expected to increase by 2034.
• In November 2024:- Keymed Biosciences Co.Ltd- A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of Stapokibart Injection in Patients With Allergic Rhinitis. Allergic rhinitis (AR) is a non infectious chronic inflammatory disease of the nasal mucosa that is mainly mediated by immunoglobulin E (IgE) in atopic individuals exposed to allergens. This study is a Randomized, Double-blind, Placebo-controlled phase II clinical study evaluating the efficacy and safety of Stapokibart injection in patients with allergic rhinitis.
• In November 2024:- Wecare Probiotics Co. Ltd- The Effectiveness of Weizmannia Coagulans BC99 in Alleviating Allergic Rhinitis in Adults and Its Impact on the Gut Microbiota. Assessing the clinical efficacy of weizmannia coagulans BC99 in alleviating allergic rhinitis symptoms, improving gut microbiota, and reducing adverse reactions in patients.
• Some of the leading Allergic Rhinitis companies working in the market are Regeneron, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Inc., Abdi Ibrahim Pharmaceuticals, Inmunotek, NeuCen BioMed, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Emergo Therapeutics, Inimmune, Paradigm Biopharmaceuticals, Siolta Therapeutics, Revelation Biosciences Inc., Allergy Therapeutics, Marinomed Biotech, Dobecure, Hyloris Pharmaceuticals, and others.
• Allergic Rhinitis Therapies that have been approved in the 7MM, including XOLAIR by Novartis Pharmaceuticals (Japan), ODACTRA/ACARIZAX/MITICURE (SLIT-tablet) by ALK-Abello, GRASTEK/GRAZAX (Grass pollen allergy vaccine tablet) by ALK-Abello, ITULAZAX, RAGWITEK/RAGWIZAX, CEDARCURE by ALK-Abello, Stallergenes Greer’s ACTAIR (STG320) and ORALAIR, Glenmark Pharmaceuticals’ (RYALTRIS), BILAXTEN/BILANOA by FAES Farma/Taiho Pharmaceutical, RUPAFIN by Mitsubishi Tanabe Pharma Corporation, DESALEX by Kyorin Pharmaceutical Co, and ALLESAGA TAPE by Hisamitsu Pharmaceutical Co., Inc.(Japan)
• As per the Asthma and Allergy Foundation of America: Allergic Rhinitis, often called hay fever. It affects 6.1 million of the children population and 20 million of the adult population in the United States.
• According to the study conducted by Susann Forkel et al. 2020: In Germany, plantain is currently the best choice to screen Allergic Rhinitis patients for weed allergy which identifies 86% of all weed-sensitized individuals. It is being demonstrated that over the last 20 years, there was a significant rise in the total number of weed pollen sensitization as well as increases in polysensitization, predominantly in younger patients.
• Allergic Rhinitisis slightly more common in males in childhood than in females.

Allergic Rhinitis Overview

Allergic Rhinitis (AR), also known as hay fever, is a type of inflammation in the nose that occurs when the immune system overreacts to allergens in the air. It is usually a long-standing condition that often goes undetected in the primary-care setting. The classic symptoms of the disorder are nasal congestion, nasal itch, rhinorrhea and sneezing.

Some people only get Allergic Rhinitis for a few months at a time because they are sensitive to seasonal allergens, such as tree or grass pollen. Other people get Allergic Rhinitis all year round. Most people with Allergic Rhinitis have mild symptoms that can be easily and effectively treated. But for some people symptoms can be severe and persistent, causing sleep problems and interfering with everyday life.

Learn more about Allergic Rhinitis treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/allergic-rhinitis-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=apr

Allergic Rhinitis market

The Allergic Rhinitis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Allergic Rhinitis market trends by analyzing the impact of current Allergic Rhinitis therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Allergic Rhinitis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Allergic Rhinitis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Allergic Rhinitis market in 7MM is expected to witness a major change in the study period 2020-2034.

Allergic Rhinitis Epidemiology

The Allergic Rhinitis epidemiology section provides insights into the historical and current Allergic Rhinitis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Allergic Rhinitis market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Allergic Rhinitis Epidemiology @ Allergic Rhinitis Market Dynamics

Allergic Rhinitis Drugs Uptake

This section focuses on the uptake rate of the potential Allergic Rhinitis drugs recently launched in the Allergic Rhinitis market or expected to be launched in 2020-2034. The analysis covers the Allergic Rhinitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Allergic Rhinitis Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Allergic Rhinitis market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Allergic Rhinitis Pipeline Development Activities

The Allergic Rhinitis report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Allergic Rhinitis key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Allergic Rhinitis pipeline development activities @ https://www.delveinsight.com/report-store/allergic-rhinitis-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=apr

Allergic Rhinitis Therapeutics Assessment

Major key companies are working proactively in the Allergic Rhinitis Therapeutics market to develop novel therapies which will drive the Allergic Rhinitis treatment markets in the upcoming years are Regeneron, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Inc., Abdi Ibrahim Pharmaceuticals, Inmunotek, NeuCen BioMed, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Emergo Therapeutics, Inimmune, Paradigm Biopharmaceuticals, Siolta Therapeutics, Revelation Biosciences Inc., Allergy Therapeutics,Marinomed Biotech, Dobecure, Hyloris Pharmaceuticals, and others.

Learn more about the emerging Allergic Rhinitis therapies & key companies @ Allergic Rhinitis clinical trials and FDA Approvals

Allergic Rhinitis Report Key Insights

1. Allergic Rhinitis Patient Population

2. Allergic Rhinitis Market Size and Trends

3. Key Cross Competition in the Allergic Rhinitis Market

4. Allergic Rhinitis Market Dynamics (Key Drivers and Barriers)

5. Allergic Rhinitis Market Opportunities

6. Allergic Rhinitis Therapeutic Approaches

7. Allergic Rhinitis Pipeline Analysis

8. Allergic Rhinitis Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Allergic Rhinitis Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Allergic Rhinitis Competitive Intelligence Analysis

4. Allergic Rhinitis Market Overview at a Glance

5. Allergic Rhinitis Disease Background and Overview

6. Allergic Rhinitis Patient Journey

7. Allergic Rhinitis Epidemiology and Patient Population

8. Allergic Rhinitis Treatment Algorithm, Current Treatment, and Medical Practices

9. Allergic Rhinitis Unmet Needs

10. Key Endpoints of Allergic Rhinitis Treatment

11. Allergic Rhinitis Marketed Products

12. Allergic Rhinitis Emerging Therapies

13. Allergic Rhinitis Seven Major Market Analysis

14. Attribute Analysis

15. Allergic Rhinitis Market Outlook (7 major markets)

16. Allergic Rhinitis Access and Reimbursement Overview

17. KOL Views on the Allergic Rhinitis Market

18. Allergic Rhinitis Market Drivers

19. Allergic Rhinitis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Allergic Rhinitis Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, NDA Approvals, Medication, Prevalence, MOA, Revenue, Statistics and Companies by DelveInsight

“Atopic Dermatitis Drugs Market”

(Albany, USA) DelveInsight’s “Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Atopic Dermatitis, historical and forecasted epidemiology as well as the Atopic Dermatitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Atopic Dermatitis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Atopic Dermatitis market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Atopic Dermatitis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Atopic Dermatitis market.

Request for sample page @ Atopic Dermatitis Market Forecast

Key Takeaways from the Atopic Dermatitis Market Report

• According to DelveInsight, Atopic Dermatitis market size is expected to grow at a decent CAGR by 2034.
• Atopic Dermatitis Market Size in 7MM was around USD 17 billion in 2023, which is expected to increase by 2034.
• Leading Atopic Dermatitis Companies in the treatment market Sanofi/Regeneron Pharmaceuticals, RAPT Therapeutics, Pfizer, Japan Tobacco, and Torii Pharmaceutical, Eli Lilly and Company, AbbVie, LEO Pharma, Incyte Corporation, Arena Pharmaceuticals, Oneness Biotech, Galderma, DS Biopharma, Janssen, AOBiome Therapeutics, Kymab, Qurient, Arcutis Biotherapeutics, Cara Therapeutics, Vanda Pharmaceuticals, and others.
• Promising Atopic Dermatitis Pipeline Therapies in the various stages of development include Baricitinib, si-544, Lebrikizumab, MEDI9929, Dupilumab, Midazolam, Omeprazole, Emollient, and others.
• In December 2024, Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, has announced interim results from its randomized, double-blind, placebo-controlled Phase 1 clinical trial of soquelitinib in patients with moderate to severe atopic dermatitis. The findings revealed a positive safety and efficacy profile, bolstering the continued development of soquelitinib for atopic dermatitis and highlighting the potential of ITK inhibition as a new therapeutic approach for other immune-related diseases.
• In November 2024, Concerto Biosciences administered the first dose in a Phase I trial of its three-strain live biotherapeutic product, ENS-002, designed to treat atopic dermatitis. ENS-002 targets Staphylococcus aureus (S. aureus), a major contributor to skin inflammation, and is being developed to address this condition.
• In October 2024, Eli Lilly’s EBGLYSS showed significant improvement in skin condition and itch relief for patients with moderate-to-severe atopic dermatitis, as highlighted by new Phase IIIb ADapt study results. These outcomes are particularly notable for individuals who did not respond adequately to the commonly prescribed dupilumab. The 24-week, open-label Phase IIIb ADapt study evaluated the safety and efficacy of EBGLYSS in patients aged 12 to under 18 years who had previously received dupilumab treatment.
• In September 2024, Galderma has announced plans to present new findings from the ARCADIA and OLYMPIA clinical trial programs, which evaluate nemolizumab for atopic dermatitis and prurigo nodularis, at the 2024 European Academy of Dermatology and Venereology (EADV) congress in Amsterdam. Scheduled for Wednesday, September 25, the presentations will include late-breaking data on long-term efficacy and safety from an interim analysis of the Phase III ARCADIA long-term extension study and novel biomarker analyses in adolescents and adults with moderate-to-severe atopic dermatitis. Additionally, Phase IIIb OLYMPIA DURABILITY study results showcasing the durability of nemolizumab’s response in adults with prurigo nodularis will also be shared.
• In August 2024, Lynk Pharmaceuticals announced promising results from its Phase Ib clinical trial of LNK01004, a novel topical therapy for atopic dermatitis. This randomized, double-blind, placebo-controlled, multicenter study evaluated the safety, tolerability, and pharmacokinetics of LNK01004 in adults with mild to moderate atopic dermatitis.
• In the 7MM, the United States had the largest market size for atopic dermatitis in 2023, with Japan following closely behind.
• DUPIXENT, the first approved therapy for atopic dermatitis (AD), generates around USD 2 billion in revenue by focusing on the moderate-to-severe patient group through targeted therapies and biologics.
• In 2023, there were approximately 53,348,000 diagnosed cases of atopic dermatitis across the 7MM, and it is anticipated that this number will rise in the forecast period from 2024 to 2034.
• In 2023, there were approximately 72,435,000 prevalent cases of atopic dermatitis across the 7MM, and it is projected that these numbers will increase during the forecast period from 2024 to 2034.
• In 2023, the total diagnosed cases of atopic dermatitis were approximately 23,481,000 for males and about 29,866,000 for females across the 7MM.
• The Atopic Dermatitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Atopic Dermatitis pipeline products will significantly revolutionize the Atopic Dermatitis market dynamics.The treatment in Japan for atopic dermatitis is similar to that of the US and EU4, and the UK. The Japanese market uses DUPIXENT, RINVOQ, CIBINQO, ADBRY/ADTRALZA, CORECTIM, OLUMIANT, MOIZERTO, and MITCHGA.
• April 2024: Suzhou Zelgen Biopharmaceuticals Co.,Ltd- A Phase I/II Study Of The Efficacy,Safety and PharmacokineticsOf Jaktinib Hydrochloride Cream In Subjects With Mild To Moderate Atopic Dermatitis. This study includes a dose escalation part and a dose extension part.
• April 2024: Pfizer- A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-07275315 AND PF-07264660 IN ADULT PARTICIPANTS WITH MODERATE-SEVERE ATOPIC DERMATITIS. The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction.
• April 2024: Eli Lilly and Company- An Open-Label, Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab. The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) previously treated with Dupilumab.

Discover more about therapies set to grab major Atopic Dermatitis market share @ Atopic Dermatitis Market Outlook

Atopic Dermatitis Overview

Atopic dermatitis (AD), commonly known as eczema, is a chronic inflammatory skin condition characterized by dry, itchy, and inflamed skin. It is most prevalent in children but can affect individuals of all ages. Atopic dermatitis is associated with immune system dysfunction, a compromised skin barrier, and genetic and environmental factors. Common triggers include allergens, irritants, stress, weather changes, and microbial infections.

Symptoms of Atopic dermatitis vary in severity and include redness, swelling, scaling, and oozing lesions, often occurring on the face, hands, elbows, and knees. Persistent itching can lead to scratching, worsening the condition and increasing the risk of skin infections. AD is often linked to other atopic conditions such as asthma and allergic rhinitis, known as the “atopic triad.”

Atopic dermatitis Management focuses on restoring the skin barrier, reducing inflammation, and preventing flare-ups. Treatment includes regular moisturizing, avoiding triggers, and using topical corticosteroids or calcineurin inhibitors. In moderate to severe cases, systemic treatments like biologics (e.g., dupilumab), immunosuppressants, and phototherapy may be considered.

Early Atopic dermatitis diagnosis and a personalized treatment approach are essential for improving quality of life and preventing complications. Patient education on skincare routines and trigger management plays a key role in controlling Atopic dermatitis.

Atopic Dermatitis Epidemiology Segmentation

• Atopic Dermatitis Prevalent Population
• Diagnosed Prevalent Population of Atopic Dermatitis
• Severity-specific Distribution of Atopic Dermatitis in Adults
• Severity-specific Distribution of Atopic Dermatitis in Pediatric Population
• Gender-specific Distribution of Atopic Dermatitis in Adults
• Chronic Pruritus Prevalence in Atopic Dermatitis in the adults

Download the report to understand which factors are driving Atopic Dermatitis epidemiology trends @ Atopic Dermatitis Market Dynamics

Atopic Dermatitis Emerging Drugs

Rocatinlimab (KHK4083/AMG 451): Amgen/Kyowa Kirin

Rocatinlimab (KHK4083/AMG 451) is an anti-OX40 human monoclonal antibody that inhibits and reduces the number of OX40-expressing pathogenic T cells responsible for driving systemic and local inflammatory responses. It has been reported that effector T cells expressing OX40 are present in the lesions of patients with Atopic Dermatitis and are critical in the disease pathophysiology. The initial antibody was discovered in collaboration between Kyowa Kirin US Research and La Jolla Institute for Immunology.

Amgen and Kyowa Kirin have recently begun recruiting participants for a comprehensive, global Phase III program (ROCKET program) to investigate the safety and efficacy of rocatinlimab in a heterogeneous moderate-to-severe AD population suffering from a high burden of disease.

Atopic Dermatitis Market Dynamics

Atopic Dermatitis market to expand because of the emergence of several novel mechanisms such as oral/topical JAK Inhibitors, PDE Inhibitors, IL-13 Inhibitors, leukotriene inhibitors, Kappa opioid receptor (KOR) agonist, NK-1 receptor antagonist, and others in the upcoming market of Atopic Dermatitis and pruritus in Atopic Dermatitis. Increased public awareness, improved access to health services, reimbursements, and financial support may boost the Atopic Dermatitis and pruritus in the market and improve the Atopic Dermatitis market accessibility of the emerging drugs.

To know more about Atopic Dermatitis Therapies and Drug options, visit @ Atopic Dermatitis Treatment Market

Atopic Dermatitis Pipeline Companies

The developing pipeline of Atopic Dermatitis holds budding key players such as lebrikizumab (Eli Lilly), nemolizumab/CD14152 (Galderma), difamilast (Otsuka Pharmaceuticals), and roflumilast (Arcutis Biotherapeutics). These emerging drugs, predicted to be launched during the forecast period, are likely to change the current market dynamics of disease treatment, thereby boosting the current Atopic Dermatitis market size. Following the late-stage products, a wide array of mid-stage or Phase II promising interventions are expected to be launched soon in the Atopic Dermatitis market, including B244 (AOBiome Therapeutics), etrasimod/APD334 (Arena Pharmaceuticals), FB825 (Oneness Biotech), DS107 (DS Biopharma), bermekimab (Janssen), KY1005 (Sanofi/Kymab), and Q301 (Zileuton) (Qurient).

Learn more about the Atopic Dermatitis Pipeline Therapies @ Atopic Dermatitis Clinical Trials and Advancements

Scope of the Atopic Dermatitis Pipeline Report

• Coverage- 7MM
• Atopic Dermatitis Companies- Sanofi (NYSE: SNY), Regeneron Pharmaceuticals (NYSE: REGN), Pfizer (NYSE: PFE), Japan Tobacco, Torii Pharmaceutical (NYSE: TRXPF), Eli Lilly and Company (NYSE: LLY), AbbVie (NYSE: ABBV), LEO Pharma, Incyte Corporation (NYSE: INCY), Arena Pharmaceuticals, Oneness Biotech, Galderma, DS Biopharma, Janssen (NYSE: JNJ), AOBiome Therapeutics, Kymab, Qurient (NYSE: KRX), Arcutis Biotherapeutics (NYSE: ARQT), Cara Therapeutics (NYSE: CARA), Vanda Pharmaceuticals (NYSE: VNDA), and others.
• Atopic Dermatitis Pipeline Therapies include Baricitinib, Dupilumab, Lebrikizumab, and others.
• Atopic Dermatitis Market Dynamics: Atopic Dermatitis Market Drivers and Barriers

Table of Content

1. Key Insights
2. Atopic Dermatitis Report Introduction
3. Atopic Dermatitis (AD) Market Overview at a Glance
4. Epidemiology and Market Methodology
5. Executive Summary
6. Atopic Dermatitis Disease Background and Overview
7. Atopic Dermatitis Epidemiology and Patient Population
8. Atopic Dermatitis Patient Journey
9. Key Endpoints in Atopic Dermatitis Clinical Trials
10. Atopic Dermatitis Marketed Therapies
11. Atopic Dermatitis Emerging Therapies
12. Atopic Dermatitis (Atopic Dermatitis): The 7MM Analysis
13. Atopic Dermatitis Market Access and Reimbursement
14. Atopic Dermatitis KOL Views
15. Atopic Dermatitis SWOT Analysis
16. Atopic Dermatitis Unmet Needs
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/aacr-annual-meeting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Atopic Dermatitis Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Patient Pool, MOA, ROA and Companies by DelveInsight